The impact of Allergic Rhinitis in clinical practice: An International Survey

D. Passali, G.C. Passali, V. Damiani, F.M. Passali, C. Cingi, S. Di Girolamo, G. Ciprandi, International Study Group

Article ID: 5538
Vol 35, Issue 1S2, 2021
DOI: https://doi.org/10.23812/21-1supp2-8
Received: 11 March 2021; Accepted: 11 March 2021; Available online: 11 March 2021; Issue release: 11 March 2021

Abstract

Allergic rhinitis (AR) is a frequent disease caused by an IgE-mediated inflammation of the nose and characterized by typical symptoms. Diagnostic workup is directed to document the production of specific IgE (sensitization). Clinical management aims to relieve symptoms, resolve allergic inflammation, use medications, and potentially induce allergen tolerance, using allergen immunotherapy (AIT). The current survey was conducted in 17 International ear nose throat experts using a questionnaire with 20 questions concerning the practical management of AR patients. It was administered in the 2021 summer. The large majority (94%) of participants use the ARIA classification in clinical practice. On average, subjects with suspected AR represent half of the patients who turn to the ENT experts; 80% have the confirmed diagnosis. Most of the experts use both cutaneous and serum assay to document IgE production. Antihistamines are prescribed in 59% of AR patients, intranasal corticosteroids in 69%, non-adrenergic decongestants in 88%, nasal lavage in 88%, and AIT in 22%. About 68% of AR patients had turbinate hypertrophy, which requires surgery in 62% (mostly surgical decongestion). In conclusion, the current International Survey demonstrated that AR is a common disorder worldwide, the diagnostic workup is mainly based on IgE assessment, and the therapeutic approach is also based on non-pharmacological remedies.


Keywords

Allergic rhinitis;Italy;survey;general population;questionnaire;on the road


References

Supporting Agencies



Copyright (c) 2021 D. Passali, G.C. Passali, V. Damiani, F.M. Passali, C. Cingi, S. Di Girolamo, G. Ciprandi, International Study Group on Allergic Rhinitis




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).